Biodesix (BDSX) Cost of Revenue (2019 - 2026)

Biodesix (BDSX) has 8 years of Cost of Revenue data on file, last reported at $4.2 million in Q1 2026.

• Quarterly Cost of Revenue rose 13.56% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.2 million (up 6.96% YoY) and the FY2025 annual result came in at $16.7 million, up 7.36% from the prior year.
• Cost of Revenue declined to $4.2 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $4.9 million in Q4 2025 to a low of $3.2 million in Q1 2023.
• A 5-year average of $3.7 million and a median of $3.7 million in 2025 frame the typical range for Cost of Revenue.
• The widest YoY moves for Cost of Revenue: up 33.47% in 2022, down 82.24% in 2022.
• Tracing BDSX's Cost of Revenue over 5 years: stood at $3.3 million in 2022, then increased by 2.06% to $3.4 million in 2023, then rose by 28.69% to $4.3 million in 2024, then increased by 12.37% to $4.9 million in 2025, then dropped by 13.81% to $4.2 million in 2026.
• The last three Cost of Revenue figures came in at $4.2 million (Q1 2026), $4.9 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.